Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b program for NXP900.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
- Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
- Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
- Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma
- Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright